UNSPSC 51182205: Doxaprost

This classification denotes a prostaglandin analogue with the molecular formula C21H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W3G873MK03, chemically known as prost-13-en-1-oic acid, 15-hydroxy-15-methyl-9-oxo-, (13e) but generally known as doxaprost, which bears US NIH Compound Identifier 6441612. European Medicines Agency schedules Doxaprost in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06383MIG.

UNSPSC 51182205 Doxaprost is a Commodity code capturing individual pharmaceutical active ingredients and compounds supplied through state and local cooperative purchasing vehicles. The scope of work encompasses the supply of specific pharmaceuticals identified by National Drug Code, including doxaprost, to state agencies, local government facilities, and participating members of multistate purchasing alliances. Solicitations under this code require manufacturers or authorized distributors to meet cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, and FDA approval; maintain contractual relationships with approved pharmaceutical wholesalers equipped with chargeback systems; and deliver products in designated packaging configurations with pricing submitted through standardized electronic formats. Issuing bodies under this code include state departments of administration and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local government members across multiple jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, including individual drug substances like doxaprost, for distribution across participating state and local government facilities in Minnesota and Oregon. The solicitation requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC), with pricing competitiveness weighted at 75 percent of the evaluation, compliance with administrative fee requirements at 5 percent, EDI capability at 5 percent, fixed pricing at 10 percent, and agreement to a 3 percent administrative fee at 5 percent. Contract awards are effective July 1, 2026, with a two-year term for new respondents and optional extensions at MMCAP's discretion. No specific award value or budget range was disclosed in the solicitation materials, and no set-aside designations limiting responses to particular business classifications were identified.